Immuneering (IMRX) Other financing activities (2022 - 2026)

Immuneering's Other financing activities history runs 5 years deep, the most recent figure standing at $10435.0 for Q1 2026.

• In Q1 2026, Other financing activities fell 92.21% year-over-year to $10435.0; the TTM figure through Mar 2026 stood at $298453.0 (down 51.78% YoY), while the FY2025 annual figure was $421910.0, down 42.4% from the prior year.
• Other financing activities for Q1 2026 stood at $10435.0, up from -$24.6 million in the prior quarter.
• The five-year high for Other financing activities was $24.9 million in Q3 2025, with the low at -$24.6 million in Q4 2025.
• The 5-year median for Other financing activities is $87995.0 (2022), against an average of $119376.2.
• Peak annual rise in Other financing activities reached 7049.61% in 2025, while the deepest fall reached 6969.11% in 2025.
• Immuneering's Other financing activities stood at $42098.0 in 2022, then plunged by 81.39% to $7835.0 in 2023, then surged by 4466.76% to $357806.0 in 2024, then tumbled by 6969.11% to -$24.6 million in 2025, then soared by 100.04% to $10435.0 in 2026.
• Business Quant data shows IMRX's Other financing activities at $10435.0 in Q1 2026, -$24.6 million in Q4 2025, and $24.9 million in Q3 2025.